nach oben

Archives of Dermatological Research

Erschienen in:

20.01.2022 | Original Paper

Racial/ethnic differences in treatment efficacy and safety for moderate-to-severe plaque psoriasis: a systematic review

verfasst von: Jessica E. Ferguson, Edward W. Seger, Jacob White, Amy McMichael

Erschienen in: Archives of Dermatological Research | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Biologic medications have revolutionized treatment of psoriasis; however, there remains uncertainty in which medications should be used to maximize efficacy based on race/ethnicity. The purpose was to determine if efficacy of biological medications differs based on race/ethnicity. A systematic review identified all clinical trials focused on biologic treatment outcomes from inception of database until March 5th, 2021. Included studies provided data on racial/ethnic differences in biologic skin clearance efficacy using the Psoriasis Area and Severity Index (PASI) and “clear/almost clear” scores. There were 1220 studies identified, and 24 included in the review. The races/ethnicities included were Asian (n = 2740), White (n = 9745), Black (n = 138), and Latino (n = 728). Ixekizumab provided the highest “clear/almost clear” score (90.7%, 89.4%) and PASI 75 (98.8%, 96.6%) for Asian and Latino patients, respectively. Guselkumab had the highest “clear/almost clear” score for White (86.8%) patients, while Black patients had highest “clear/almost clear” (75.0%) and PASI 75 (91.7%) scores to brodalumab. Limitations included lack of studies reporting outcome data based on race/ethnicity and lack of patients of color within psoriasis clinical trials. For treatment of plaque psoriasis, there is evidence of differences in efficacy of biologics improving clinical disease severity between different races or ethnicities.

Nur mit Berechtigung zugänglich

Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC (2021) Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds.) Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane. Available from www.training.cochrane.org/handbook

Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. Arch Dermatol. 1996; 132(4):419–423

Abe M, Nishigori C, Torii H et al (2017) Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: subgroup analyses from a randomized, placebo-controlled phase 3 trial. J Dermatol 44(11):1228–1237CrossRef

Adsit S, Zaldivar ER, Sofen H et al (2017) Secukinumab is efficacious and safe in Hispanic patients with moderate-to-severe plaque psoriasis: pooled analysis of four phase 3 trials. Adv Ther 34(6):1327–1339CrossRef

Alexis AF, Blackcloud P (2014) Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol 7(11):16–24

Asahina A, Nakagawa H, Etoh T, Ohtsuki M (2010) Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 37(4):299–310CrossRef

Asahina A, Torii H, Ohtsuki M et al (2016) Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study. J Dermatol 43(11):1257–1266CrossRef

Blauvelt A, Papp K, Gottlieb A et al (2020) A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol 182(6):1348–1358CrossRef

Blauvelt A, Reich K, Lebwohl M et al (2019) Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. J Eur Acad Dermatol Venereol 33(3):546–552CrossRef

10.

Bray JK, Cline A, McMichael AJ, Feldman SR (2021) Differences in healthcare barriers based on racial and/or ethnic background for patients with psoriasis. J Dermatolog Treat 32(6):590–594CrossRef

11.

Cai L, Gu J, Zheng J et al (2017) Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol 31(1):89–95CrossRef

12.

Chigutsa E, Velez de Mendizabal N, Chua L et al (2018) Exposure-response modeling to characterize the relationship between ixekizumab serum drug concentrations and efficacy responses at week 12 in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 58(11):1489–1500CrossRef

13.

Chiu HY, Huang PY, Jee SH et al (2012) HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis. Br J Dermatol 166(2):288–297CrossRef

14.

Chou CT (2006) The clinical application of etanercept in Chinese patients with rheumatic diseases. Mod Rheumatol 16(4):206–213CrossRef

15.

Davis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, McMichael AJ (2012) Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol 11(4):466–473

16.

Disphanurat W, Viarasilpa W, Chakkavittumrong P, Pongcharoen P (2019) The clinical effect of oral vitamin D2 supplementation on Psoriasis: a double-blind, randomized, placebo-controlled study. Dermatol Res Pract 2019:5237642CrossRef

17.

Forand RL (2021) Patients with psoriasis, skin of color experience disparities in identification, treatment. Healio Psoriatic Disease 2021(1). https://www.healio.com/news/dermatology/20210212/patients-withpsoriasis-skin-of-color-experience-disparities-in-identification-treatment

18.

Gordon KB, Blauvelt A, Foley P et al (2018) Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol 178(1):132–139CrossRef

19.

Gratacós J, Casado E, Real J, Torre-Alonso JC (2007) Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 66(4):493–497CrossRef

20.

Hafez VG, Bosseila M, Abdel Halim MR, Shaker OG, Kamal M, Kareem HS (2015) Clinical effects of “pioglitazone”, an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1. J Dermatolog Treat 26(3):208–214CrossRef

21.

Hutmacher MM, Nestorov I, Ludden T, Zitnik R, Banfield C (2007) Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis. J Clin Pharmacol 47(2):238–248CrossRef

22.

Igarashi A, Kato T, Kato M, Song M, Nakagawa H (2012) Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 39(3):242–252CrossRef

23.

Imafuku S, Torisu-Itakura H, Nishikawa A, Zhao F, Cameron GS (2017) Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1). J Dermatol 44(11):1285–1290CrossRef

24.

Imafuku S, Nakagawa H, Igarashi A et al (2021) Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: results from a 5-year extension of a phase 3 study (reSURFACE 1). J Dermatol 48(6):844–852CrossRef

25.

Kaufman BP, Alexis AF (2018) Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of Psoriasis in Non-White Racial/Ethnic Groups. Am J Clin Dermatol 19(3):405–423CrossRef

26.

Kavanaugh A, Husni ME, Harrison DD et al (2017) Safety and efficacy of intravenous Golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. Arthritis Rheumatol 69(11):2151–2161CrossRef

27.

Lee MG, Huang YH, Lee JH et al (2019) Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: subgroup analysis from the CLEAR study. J Dermatol 46(9):752–758CrossRef

28.

Mayser P, Mrowietz U, Arenberger P et al (1998) Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol 38(4):539–547CrossRef

29.

McMichael A, Desai SR, Qureshi A, Rastogi S, Alexis AF (2019) Efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis and skin of color: results from the Pooled AMAGINE-2/-3 Randomized Trials. Am J Clin Dermatol 20(2):267–276CrossRef

30.

Mease PJ, Gladman DD, Ritchlin CT et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279–3289CrossRef

31.

Menter A, Tyring SK, Gordon K et al (2008) Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58(1):106–115CrossRef

32.

Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM (2010) Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 63(3):448–456CrossRef

33.

Menter MA, Papp KA, Cather J et al (2016) Efficacy of tofacitinib for the treatment of moderate-to-severe chronic plaque psoriasis in patient subgroups from two randomised phase 3 trials. J Drugs Dermatol 15(5):568–580

34.

Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1CrossRef

35.

Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A (2012) Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial. J Dermatol 39(9):761–769CrossRef

36.

Nakagawa H, Niiro H, Ootaki K (2016) Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci 81(1):44–52CrossRef

37.

Nishikawa R, Nagai H, Bito T et al (2016) Genetic prediction of the effectiveness of biologics for psoriasis treatment. J Dermatol 43(11):1273–1277CrossRef

38.

Noda S, Mizuno K, Adachi M (2012) Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital. J Dermatol 39(3):265–268CrossRef

39.

Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M et al (2018) Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics 19(1):7–16CrossRef

40.

Pariser D, Frankel E, Schlessinger J et al (2018) Efficacy of Secukinumab in the treatment of moderate to severe plaque psoriasis in the North American subgroup of patients: pooled analysis of four phase 3 studies. Dermatol Ther 8(1):17–32CrossRef

41.

Paul C, Lacour JP, Tedremets L et al (2015) Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 29(6):1082–1090CrossRef

42.

Rachakonda TD, Schupp CW, Armstrong AW (2014) Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 70(3):512–516CrossRef

43.

Reddy VD, Myers BA, Chan SY et al (2021) A review of current phase III clinical trials of plaque psoriasis: under-representation of nonwhite participants and need for reform. Br J Dermatol 184(2):348–350CrossRef

44.

Saeki H, Nakagawa H, Ishii T et al (2015) Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 29(6):1148–1155CrossRef

45.

Saurat JH, Stingl G, Dubertret L et al (2007) Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158(3):558–566CrossRef

46.

Sbidian E, Chaimani A, Garcia-Doval I et al (2021) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 4(4):CD011535

47.

Stengel FM, Petri V, Campbell GAM et al (2009) Control of moderate-to-severe plaque psoriasis with Efalizumab: 24-week, open-label, phase IIIb/IV Latin American Study Results. Arch Drug Inf 2(4):71–78CrossRef

48.

Strober B, Menter A, Leonardi C et al (2020) Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol 34(12):2830–2838CrossRef

49.

Takeshita J, Eriksen WT, Raziano VT et al (2019) Racial differences in perceptions of psoriasis therapies: implications for racial disparities in psoriasis treatment. J Invest Dermatol 139(8):1672-1679.e1671CrossRef

50.

Trong HN, Tat TN, Anh TTN et al (2019) Efficacy of adding oral simvastatin to topical therapy for treatment of Psoriasis: the Vietnamese experience. Open Access Maced J Med Sci 7(2):237–242CrossRef

51.

Tsai TF, Ho JC, Song M et al (2011) Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 63(3):154–163CrossRef

52.

Valenzuela F, de la Cruz FC, Galimberti RL et al (2017) Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study. Actas Dermosifiliogr 108(6):550–563CrossRef

53.

Van ED, Diem TP, Thi VB et al (2019) Successful psoriasis treatment using NB-UVB with methotrexate: the Vietnamese experience. Open Access Maced J Med Sci 7(2):253–255CrossRef

54.

Wu N-L, Hsu C-J, Sun F-J, Tsai T-F (2017) Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: subanalysis from ERASURE phase III study. J Dermatol 44(10):1129–1137CrossRef

55.

Yang HZ, Wang K, Jin HZ et al (2012) Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J (Engl) 125(11):1845–1851

56.

Zandvliet A, Glasgow S, Horowitz A et al (2015) Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects. Int J Clin Pharmacol Ther 53(2):139–146CrossRef

57.

Zhang J, Tsai T-F, Lee M-G et al (2017) The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a Phase 3, randomized, double-blind, placebo-controlled study. J Dermatol Sci 88(1):36–45CrossRef

58.

Zhu X, Zheng M, Song M et al (2013) Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol 12(2):166–174

59.

Zhu Y, Wang Q, Frederick B et al (2013) Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies. Clin Drug Investig 33(4):291–301CrossRef

Titel: Racial/ethnic differences in treatment efficacy and safety for moderate-to-severe plaque psoriasis: a systematic review
verfasst von: Jessica E. Ferguson
Edward W. Seger
Jacob White
Amy McMichael
Publikationsdatum: 20.01.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Dermatological Research / Ausgabe 1/2023
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-022-02324-4

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Diagnostic work-up and treatment in patients with pyoderma gangrenosum: retrospective analysis of US insurance claims-based data

Skin substitutes for the management of mohs micrographic surgery wounds: a systematic review

Clinical and pathological features associated with high-risk, multiple, and recurrent basal cell carcinomas: a retrospective cohort analysis from the Levantine coast of the Mediterranean Sea

Impact of COVID-19 on dermatologic surgery: experience of a Midwestern academic practice

Reappraisal and literature review of primary cutaneous cribriform apocrine carcinoma